Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 13/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.45 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552879 | 0.89 | PDK2 (0.52) | PDK2JAK2 | |
| SCHEMBL21749289 | 0.87 | PDK2 (0.50) | PDK2PDK1PDK3TYRO3AXL | |
| SCHEMBL20552657 | 0.81 | JAK1 (0.43) | PDK2JAK2JAK3PTK2 | |
| SCHEMBL20552900 | 0.81 | ABL1 (0.38) | PDK2PDK1PDK3JAK2JAK3 | |
| SCHEMBL21749306 | 0.80 | FLT1 (0.46) | NAMPT | |
| SCHEMBL20552661 | 0.79 | BRAF (0.42) | JAK2JAK3PTK2 | |
| SCHEMBL20552643 | 0.78 | ABCG2 (0.47) | — | |
| SCHEMBL16481432 | 0.77 | KIF11 (0.52) | — | |
| SCHEMBL20551821 | 0.77 | PDK2 (0.52) | PDK2 | |
| SCHEMBL20552685 | 0.77 | TEAD1 (0.46) | PDK2JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | PDK2 267/4885PDK1 26/4885PDK3 141/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | PDK2 267/4885PDK1 26/4885PDK3 141/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | PDK2 3742/4885PDK1 1985/4885PDK3 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.